The psoriasis drug was one of 10 J&J medicines that grew double digits in the third quarter, leading the company to raise guidance for the year.

Pfizer agreed to pay $250m up front for worldwide rights to a Phase II drug that could target a broad population in cardiovascular disease. Scrip talked to Pfizer's head of internal medicine research about it.

"We're planning for success," John Thero told Scrip in an interview, where he talked about the upcoming US advisory committee meeting for Vascepa, commercial expansion plans and deflected questions about a big pharma buyout.

The company filed an sNDA with the US FDA for the triple combination, hoping to expand its current COPD indication to also include asthma.

Less than one month into the job, Sanofi CEO Paul Hudson talked about his early perspective on how he can build on Sanofi's strengths and deliver needed changes.

The detailed data from PROfound showed the PARP inhibitor doubled the time to radiographic progression-free survival in men with homologous recombination repair (HRRm) gene mutations.